AIxCrypto Plans $10 Million Purchase of Faraday Future Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: PRnewswire
- Strategic Investment: AIxCrypto Inc. announced plans to purchase $10 million of Faraday Future common stock, marking a strategic deployment of its blockchain infrastructure aimed at launching its tokenized Real World Asset business.
- Asset Digitization: The transaction will be facilitated by an independent third party, with AIxCrypto intending to use these shares as the foundational asset for its first tokenized equity product, thereby digitizing the equity issuance lifecycle and enhancing the connection between traditional capital markets and the on-chain economy.
- Market Access Expansion: By leveraging the liquidity and programmability of blockchain technology, AIxCrypto aims to provide broader market access for a global, digital-native investor base, strengthening its market position in the competitive fintech landscape.
- Future Outlook: Should definitive agreements be executed, AIxCrypto will provide further updates, demonstrating its proactive strategy and positioning in the rapidly evolving blockchain and fintech sectors.
Analyst Views on AIXC
About AIXC
AIxCrypto Holdings, Inc., formerly Qualigen Therapeutics, Inc., is focused on building an ecosystem that integrates Artificial Intelligence (AI) and blockchain, bridging Web2 and Web3. This ecosystem unites a decentralized protocol, distributed network, AI DePIN and EAI RWA value regeneration, and a DeAI Agent product and technology platform designed to achieve optimal trading performance. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. Its crypto business, CXC10, is centered on three growth engines which include six key products: C - Crypto 10 (C10) as Value Anchor, X - DeAI Agent, and C - RWA & Ecosystem Tokens. C - Crypto 10 (C10) as Value Anchor - through the C10 Digital Asset Treasury, C10 Index, and a potential C10 ETF. C - RWA & Ecosystem Tokens - including the C10 Stablecoin and the EAI + Crypto Dual-Bridge Real World Asset product, bridging traditional assets with Web3. It also develops and commercializes oncology and immunology therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
